Biocept, Inc. to Present at the 26th Annual ROTH Conference
SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), an oncology diagnostics company focused on improving individual patient treatment, announced today that the Company's President and Chief Executive Officer, Michael Nall will be presenting at the 26th Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
Mr. Nall is scheduled to present on Wednesday, March 12, 2014 at 10:00 a.m. Pacific Time in the Promenade Room. A live webcast of the presentation and slides will be available to the public on the Investor Relations section of the Company's website, ir.biocept.com, and the webcast will be archived for 90 days following the live event. Please allow extra time prior to the presentation to visit the Company's website and download any software that may be needed to listen to the webcast.
About Biocept:
Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its technology platforms to help improve individual patient treatment. Biocept has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and plans to introduce tests for other solid tumors.
CONTACT: Investor Contact:
The Ruth Group
David Burke/Lee Roth
(646) 536-7009 / (646) 536-7012
dburke@theruthgroup.com/lroth@theruthgroup.com
Media Contact:
The Ruth Group
Melanie Sollid-Penton
(646) 536-7023
msollid@theruthgroup.com